ATRA
Atara Biotherapeutics, Inc.
-0.67 (-6.63%)9.44USD6.5K成交股數94.8M市值–本益比(近四季)15.3股價營收比-96.4%營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 630K-96% | 516K-99% | 1.6M-96% | 3.5M-88% | 17.6M-36% | 98.1M+2208% | 40.2M+1780% | 28.6M+2893% | 27.4M | 4.3M | 2.1M | 957K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 1.3M | 164K | −223K | 2.9M | 7.3M | 27.4M | 43.9M | 33.3M | 45.5M | 49.6M | 56.9M | 56.1M |
| 銷售管理費用 | 3.8M | 3.6M | 4.3M | 4.0M | 6.5M | 11.5M | 10.4M | 8.9M | 11.1M | 11.5M | 12.2M | 13.3M |
| 營業利益 | −4.7M-248% | −3.4M-109% | −2.6M-88% | −3.6M-80% | 3.2M-110% | 38.8M-165% | −21.8M-69% | −18.2M-74% | −31.2M | −60.0M | −69.6M | −71.4M |
| 營業利益率 | -749.2% | -652.9% | -160.7% | -103.5% | 18.2% | 39.5% | -54.1% | -63.7% | -114.2% | -1,410.2% | -3,255.9% | -7,462.3% |
| 稅後淨利 | −4.8M-303% | −4.1M-111% | −3.4M-84% | −4.3M-77% | 2.4M-108% | 38.0M-163% | −21.9M-69% | −19.0M-73% | −31.8M | −60.5M | −69.8M | −71.1M |
| 淨利率 | -767.3% | -803.3% | -213.5% | -124.6% | 13.6% | 38.7% | -54.5% | -66.5% | -116.1% | -1,421.7% | -3,264.6% | -7,430.3% |
| 稀釋 EPS | -0.32-268% | -0.29-108% | -0.80-73% | -0.32-90% | 0.19-103% | 3.50-111% | -2.93-82% | -3.10-82% | -5.65 | -31.16 | -16.40 | -16.91 |
| 稀釋股數 | 15.0M | 14.1M | 12.7M | 13.6M | 12.3M | 10.9M | 7.5M | 6.1M | 5.6M | 4.2M | 4.3M | 4.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 3.2M | 8.4M | 8.5M | 5.7M | 16.9M | 13.8M | 46.5M | 31.3M | 35.1M | 25.8M | 64.8M | 45.9M |
| 應收帳款 | 318K | 0.00 | 1.3M | 1.9M | 0.00 | 8.9M | 1.3M | 2.4M | 35.8M | 34.1M | 163K | 507K |
| 存貨 | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 14.0M | 18.7M | 16.1M | 9.7M | 6.6M | 7.9M |
| 總資產 | 21.0M | 20.0M | 20.2M | 30.2M | 36.9M | 62.0M | 143M | 117M | 165M | 166M | 189M | 246M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 58.0M | 57.3M | 58.7M | 66.8M | 71.9M | 117M | 233M | 228M | 264M | 265M | 240M | 239M |
| 股東權益 | −37.0M | −37.3M | −38.5M | −36.6M | −35.0M | −55.1M | −90.5M | −111M | −98.3M | 99.2M | −50.8M | 7.5M |
| 負債比 | 276.0% | 286.6% | 290.3% | 221.4% | 195.0% | 188.8% | 163.4% | 194.5% | 159.5% | 160.0% | 126.9% | 97.0% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −3.1M-89% | – | – | – | −28.1M | – | – | −29.6M | – | – | – |
| 資本支出 | – | – | – | – | – | 0.00 | – | – | 127K | – | – | – |
| 自由現金流 | – | – | – | – | – | −28.1M | – | – | −29.7M | – | – | – |
| 折舊攤銷 | – | 29K | – | – | – | 1.8M | – | – | 1.4M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | -28.7% | – | – | -108.7% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 121M | -6.3% | 32.7M | 27.1% | 2.57 | −50.9M |
| FY2024 | 129M | +1404.0% | −85.4M | -66.2% | -11.41 | −69.0M |
| FY2023 | 8.6M | -86.5% | −276M | -3,220.9% | -65.19 | −194M |
| FY2022 | 63.6M | – | −228M | -359.1% | -2.24 | −275M |
| FY2021 | – | – | −340M | –% | -3.63 | −231M |
| FY2020 | – | – | −307M | –% | -4.15 | −185M |
| FY2019 | – | – | −291M | –% | -5.67 | −241M |
| FY2018 | – | – | −231M | –% | -5.27 | −216M |